Filana Therapeutics IncFLNA
Price$0.96

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Net Income -$77.9MTTM through 31 Mar 2026
Free Cash Flow -$30.2MTTM through 31 Mar 2026

Margins

Current

Returns

-114.3%ROE
-71.9%ROA

Balance Sheet Health

Current Ratio2.19x
Cash & Equivalents$86.6M

Quality Metrics

Piotroski F-Score1 / 9
Earnings-Beat Rate100.0%

Multi-Year Trend

Diluted EPS-$1.88TTM
'13'14'15'22'23'24'25
FY2025: $-1.88

Dividend

No dividend

Capital Allocation

R&D Spend$17.5M

Segment Performance

SegmentRevenueYoYOutlook
Development of novel drugs and diagnostics$0
View details

Focusing discovery and product development efforts on central nervous system disorders, specifically developing simufilam for Tuberous Sclerosis Complex (TSC)-related epilepsy.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.